Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.59 +0.79 (+5.00%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Summit Therapeutics to Present at Upcoming Investor Conferences

February 26, 2026

From Summit Therapeutics

Via Business Wire

Summit (SMMT) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Summit (SMMT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Summit Therapeutics (NASDAQ:SMMT) Reports Widening Q4 Losses Amid Aggressive Clinical Push ↗

February 23, 2026

Via Chartmill

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

February 23, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

February 17, 2026

From Summit Therapeutics

Via Business Wire

One Fund Discloses $9 Million Ethereum ETF Exit as Crypto Market Downturn Worsens ↗

February 03, 2026

The iShares Ethereum Trust ETF provides regulated exposure to ether’s price performance for institutional and retail investors alike.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Is SharpLink Gaming Stock a Buy or Sell After Apeiron Capital Sold Its Stake Valued at $23 Million? ↗

February 02, 2026

SharpLink Gaming connects sports fans and publishers to betting operators through affiliate marketing and data-driven acquisition solutions.

Via The Motley Fool

Topics Regulatory Compliance

2 Stocks That Could Soar This Year ↗

January 31, 2026

These innovative biotechs could have plenty of upside ahead.

Via The Motley Fool

Topics Intellectual Property

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 30, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

January 29, 2026

From Summit Therapeutics

Via Business Wire

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

2 Biotech Stocks That Could Soar This Year ↗

January 12, 2026

And, if all goes well, over the next five years as well.

Via The Motley Fool

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)

January 12, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

January 12, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Summit Therapeutics

Via Business Wire

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗

January 06, 2026

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.

Via The Motley Fool

Topics Stocks

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Summit Therapeutics

Via Business Wire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗

December 10, 2025

Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that.

Via The Motley Fool

Topics Artificial Intelligence

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗

December 09, 2025

They haven't peaked yet.

Via The Motley Fool

Topics Intellectual Property

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Summit Therapeutics

Via Business Wire

Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗

December 05, 2025

The healthcare stock could skyrocket if ivonescimab obtains approval from regulators, but there's still plenty of risk here.

Via The Motley Fool

Don't Buy Summit Therapeutics Until This Big Thing Happen ↗

December 03, 2025

This biotech company is rolling the dice with a planned regulatory submission.

Via The Motley Fool

2 Monster Stocks in the Making to Buy and Hold ↗

December 02, 2025

There's still time to get in on these rising stars.

Via The Motley Fool

Summit SMMT Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Summit SMMT Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

November 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Present at Upcoming Investor Conferences

November 04, 2025

From Summit Therapeutics

Via Business Wire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

October 31, 2025

From Summit Therapeutics

Via Business Wire

Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗

October 30, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.